Business
TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap
Peer-reviewed case report by Prof. Andreas Pfützner demonstrates real-world insulin protection during extreme heat exposure and aligns with previously validated savings modelVancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating the
About this update from Tempramed Technologies Ltd.
[{"type":"text","content":"Peer-reviewed case report by Prof. Andreas Pfützner demonstrates real-world insulin protection during extreme heat exposure and aligns with previously validated savings model","length":174,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating the use of VIVI Cap™ for passive thermal protection of insulin during summer travel.","length":427,"tagName":"p"},{"type":"text","content":"The paper, titled "Passive Thermal Protection of In-Use Insulin During Summer Travel: Device Description and Single-Patient Case Report with a Simple Cost Perspective," was authored by TempraMed's Medical Director, Prof. Andreas Pfützner, and colleagues and published in the Journal of Clinical & Medical Case Reports (February 2026).","length":352,"tagName":"p"},{"type":"text","content":"The publication describes the use of VIVI Cap™ by a patient with type 1 diabetes during sustained high ambient temperatures (35-38°C) while traveling in Greece. Compared to a prior month without thermal protection, the patient demonstrated:","length":240,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Improved time-in-range (86% vs. 82%)","length":36,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reduced time above 250 mg/dL (3% vs. 5%)","length":40,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Stable mealtime insulin requirements despite extreme heat","length":57,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"No emergency department or urgent care visits","length":45,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":178,"olType":false},{"type":"text","content":"Importantly, the report emphasizes not only glycemic stability but also reduced anxiety and increased patient confidence regarding insulin effectiveness in hot climates, factors that directly influence healthcare utilization and medication wastage.","length":248,"tagName":"p"},{"type":"text","content":"Scientific Evidence ...